期刊论文

He, Housheng Hansen

英文

Cell

0092-8674

2018

174

3

564-575.e18

10.1016/j.cell.2018.06.014

The authors thank the Princess Margaret Genomic Centre for high-throughput sequencing support. The work was supported by the Princess Margaret Cancer Foundation ( 886012001223 to H.H.H.), Canada Foundation for Innovation and Ontario Research Fund ( CFI32372 to H.H.H.), NSERC discovery grant ( 498706 to H.H.H.), WICC Ontario 20th Anniversary Prostate Cancer Innovation Grant of the CCS ( 703800 to H.H.H.), CIHR operating grant ( 142246 to H.H.H.), Movember discovery grant ( D2016-1115 to H.H.H.) and Rising Star awards from Prostate Cancer Canada ( RS2014-01 to P.C.B. and RS2016-1022 to H.H.H.). H.H.H. holds a TFRI New Investigator Award, an OMIR Early Researcher Award, and a CIHR New Investigator Salary Award. J.T.H. is supported by the CIHR Graduate Student Doctoral Fellowship ( GSD146249 ). H.L. is supported by the Department of Defense (DOD) (grant W81XWH-17-1-0192 ). The results shown here are in whole or in part based upon data generated by the TCGA Research Network.

本校为其他机构

The prostate cancer (PCa) risk-associated SNP rs11672691 is positively associated with aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a short isoform of long noncoding RNA PCAT19 (PCAT19-short), which is in the third intron of the long isoform (PCAT19-long). The risk variant is associated with decreased and increased levels of PCAT19-short and PCAT19-long, respectively. Mechanistically, the risk SNP region is bifunctional with both promoter and enhancer activity. The risk variants of rs11672691 and its LD SNP...